R3 Vascular Appoints Josh Smale as its Vice President of Global Clinical and Scientific Affairs
July 09 2024 - 1:25PM
R3 Vascular Inc., a medical device company dedicated to developing
and providing novel, best-in-class bioresorbable scaffolds for
treating peripheral arterial disease (PAD), is pleased to announce
the appointment of Josh Smale as its Vice President of Global
Clinical and Scientific Affairs.
Prior to joining R3 Vascular, Mr. Smale served as Vice President
of Clinical Affairs for the Peripheral Intervention business unit
of Becton Dickinson (BD) where he was responsible for all aspects
of clinical evidence generation and dissemination for the company’s
complex and diverse device portfolio. Prior to his tenure at BD,
Mr. Smale served in roles of increasing responsibility for Bard
Peripheral Vascular, Inc. (BPV) which was acquired by BD, and as
Regulatory Affairs Manager for SenoRX, Inc. which was acquired by
BPV. He also served as Regulatory Affairs Manager for Endologix,
Inc. and in various roles at BPV. Mr. Smale holds a Bachelor of
Science in Engineering with an emphasis on Molecular and Cellular
Engineering, and Biochemical Engineering from Arizona State
University. He also served on the board of the Peripheral
Intervention business unit of BD, has received numerous awards, is
the co-author of several publications, and holds five Vena Cava
Filter patents.
Commenting on the appointment of Mr. Smale, Christopher M.
Ownes, President and CEO of R3 Vascular, said, “On behalf of the R3
management team, I am very pleased to welcome Josh Smale as Vice
President of Global Clinical and Scientific Affairs. Josh has a
proven track record and more than 20 years of relevant medical
device experience specializing in clinical and regulatory affairs
strategy, clinical evidence generation and dissemination, and
physician education. Among other key clinical and scientific
affairs programs, Josh will lead our clinical trial efforts,
including our pivotal ELITE trial for our next generation Magnitude
drug eluting bioresorbable scaffold. We look forward to his
contributions as we work towards establishing R3 Vascular as the
leader in the development and manufacturing of fully bioresorbable
vascular scaffolds.”
Mr. Smale said, “I am very excited to join R3 Vascular and work
closely with Chris Owens, Kamal Ramzipoor, and the rest of the R3
Vascular team to build upon the success of the company and support
the adoption of its breakthrough technology for treating
below-the-knee peripheral arterial disease (BTK PAD). R3 Vascular’s
novel next generation bioresorbable scaffolds will transform the
field of peripheral interventions by providing a new standard of
care and improving the health of patients around the world.”
Mr. Smale joins R3 Vascular’s leadership team which, among
others, includes Christopher M. Owens, President and Chief
Executive Officer and Kamal Ramzipoor, R3 Vascular’s Founder and
Chief Technology Officer (CTO). In May of 2024, R3 Vascular
announced the closing of its $87 million Series B financing
round.
About R3 Vascular Inc.R3 Vascular is a
privately-held medical device company that develops a novel
technology platform for the next generation of
fully bioresorbable drug eluting sirolimus coated vascular
scaffolds. These are designed to deliver the ‘stent-like’ support
of a scaffold along with the anti-inflammatory and
anti-proliferative result of sirolimus, but ‘disappearing’ over
time as the vessel heals. R3 Vascular is headquartered in Mountain
View, California. More information can be found at
www.r3vascular.com.
Media Contact:David Gutierrez, Dresner
Corporate Services, (312) 780-7204, dgutierrez@dresnerco.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/c861cb09-8ed9-4401-8f89-6e69934fd0d3